(Q45875131)

17 December 2017

title

Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines (English)

1 reference

17 December 2017

1 reference

Akiyama Y

1

1 reference

17 December 2017

Watanabe M

2

1 reference

17 December 2017

Maruyama K

3

1 reference

17 December 2017

Ruscetti FW

4

1 reference

17 December 2017

Wiltrout RH

5

1 reference

17 December 2017

Yamaguchi K

6

1 reference

17 December 2017

publication date

1 December 2000

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

7

1 reference

17 December 2017

page(s)

2113-2121

1 reference

17 December 2017

issue

24

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.gt.3301353

exact match

0 references

cites work

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

IL-12: a key cytokine in immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Inhibition of angiogenesis in vivo by interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

In vivo detection of dendritic cell antigen presentation to CD4(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

7 January 2021

CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

7 January 2021

Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

7 January 2021

Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

7 January 2021

Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301353

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3301353

1 reference

17 December 2017

Dimensions Publication ID

0 references

1 reference

17 December 2017